Srdan Verstovsek, M.D., Ph.D., is Chief, Section for Myeloproliferative Neoplasms (MPNs) in the Leukemia department, Founder/Director of the largest Clinical Research Center for MPNs worldwide, and a global leader in MPNs. Landmark therapeutics for MPN, such as ruxolitinib, were clinically developed under Dr. Verstovsek's leadership. The research studies conducted at the Clinical Research Center for MPN are frequently presented at the most important national and international conferences, for example, ASH, ASCO, and EHA. Dr. Verstovsek has authored more than 650 peer-reviewed original articles and reviews that were published in prestigious journals. The Clinical Research Center for MPNs periodically publishes the newsletter MPN Focus with the goal to educate MPN patients, caregivers, and healthcare providers about novel MPN therapeutics and the latest research findings.
The MPN team was formed in 2005. At that time, the team included one physician and one research nurse, with only one active MPN-specific clinical protocol. Since that time, the MPN team has grown exponentially and currently includes more than 8 research nurses, 4 data coordinators and 4 laboratory personnel. Dr. Verstovsek has led more than 60 early/advanced phase clinical trials of novel MPN drugs, including ruxolitinib, the only FDA-approved and cornerstone medication for myelofibrosis until 2019, and second-line treatment for polycythemia vera. Dr. Verstovsek is currently leading several pivotal phase 3 trials for highly promising myelofibrosis medications.
Elias Jabbour, M.D., Professor, Leukemia department
Prithviraj Bose, M.D., Associate Professor, Leukemia department
Naval Daver, M.D., Associate Professor, Leukemia department
Naveen Pemmaraju, M.D., Associate Professor, Leukemia department
Uday Popat, M.D., Professor, Stem Cell Transplantation department
Carlos Bueso-Ramos, M.D., Ph.D., Professor, Hematopathology department
Myeloproliferative Neoplasms (MPN) Team Members who received the 2020 Waun Ki Hong Award for Excellence in Team Science
"This vibrant and prolific MPN Team has led to
exceptional advancements in prognosis, diagnosis and treatment of
MPN that have significantly improved patient quality of life and
survival through collaborative efforts and discovery; and combined
clinical, morphologic, and molecular expertise." - Awards Committee